À¯ÀüÇÐÀû °Ë»ç ½ÃÀåÀº 2030³â±îÁö 118¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.
2023³â¿¡ 78¾ï ´Þ·¯·Î ÃßÁ¤µÈ À¯ÀüÇÐÀû °Ë»ç ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 6.1%·Î ¼ºÀåÇϰí, 2030³â¿¡´Â 118¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼¿¡¼ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Âø»óÀü À¯ÀüÀÚ Áø´Ü, ½ºÅ©¸®´× °Ë»ç´Â º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 6.9%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ Á¾·á±îÁö 46¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºñħ½ÀÀû »êÀü °Ë»ç(NIPT) ¹× ij¸®¾î ½ºÅ©¸®´× °Ë»ç ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)·Î 6.1%·Î ÃßÁ¤µË´Ï´Ù.
¹Ì±¹ ½ÃÀåÀº 21¾ï ´Þ·¯·Î ÃßÁ¤µÇ¸ç Áß±¹Àº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 9.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¹Ì±¹ÀÇ À¯ÀüÇÐÀû °Ë»ç ½ÃÀåÀº 2023³â 21¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 27¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº 9.1%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº °¢°¢ 3.3%¿Í 5.7%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼´Â µ¶ÀÏÀÌ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 3.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¼¼°è À¯ÀüÇÐÀû °Ë»ç ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ ¿ä¾à
À¯ÀüÇÐÀû °Ë»ç°¡ ¸ÂÃãÇü ÀÇ·á¿¡ Çõ¸íÀ» °¡Á®¿À´Â ÀÌÀ¯¶õ?
À¯ÀüÇÐÀû °Ë»ç´Â À¯Àü Áúȯ ¹× º´¸®Çаú °ü·ÃµÈ À¯ÀüÀÚ º¯ÀÌÀÇ °ËÃâÀ» °¡´ÉÇÏ°Ô Çϰí Çö´ë ÀǷḦ º¯È½ÃŰ´Â µµ±¸°¡ µÇ¾ú½À´Ï´Ù. À¯ÀüÇÐÀû °Ë»ç´Â À¯Àü¼º ÁúȯÀÇ Áø´Ü, °³ÀÎÈ Ä¡·á °èȹÀÇ Áöµµ, À¯ÀüÀû ÇüÁúÀ» ÀÚ¼Õ¿¡°Ô ³²±â´Â ÀáÀçÀû À§ÇèÀ» °¡Áø ȯÀÚ¿¡°Ô ÅëÁöÇϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. À¯ÀüÇÐÀû °Ë»ç´Â ¾Ï À§Çè Æò°¡, »ý½Ä ÀÇ·á, ½ÉÇ÷°ü Áúȯ µî Æø³ÐÀº ¿ëµµ¸¦ ¸Á¶óÇϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚ ½ÃÄö½Ì ºñ¿ëÀÌ °è¼Ó °¨¼ÒÇÔ¿¡ µû¶ó À¯ÀüÇÐÀû °Ë»ç´Â ´õ Ä£¼÷ÇØÁö°í °³ÀÎÀÇ °Ç° »óÅ¿¡ ´ëÇÑ ±ÍÁßÇÑ ÅëÂû·ÂÀ» Á¦°øÇϰí Á¶±â °³ÀÔ°ú ¿¹¹æ ÀǷḦ °¡´ÉÇϰÔÇÕ´Ï´Ù. À¯Àüü °úÇÐÀÇ Áøº¸·Î À¯ÀüÇÐÀû °Ë»ç´Â ÀÌÁ¦ ¸ÂÃãÇü ÀÇ·áÀÇ ±âÃʰ¡ µÇ¾î °³ÀÎÀÇ À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏÀ» ±â¹ÝÀ¸·Î ¸ÂÃãÇü ÀÇ·á ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù.
±â¼úÀÇ Áøº¸´Â À¯ÀüÇÐÀû °Ë»ç ½ÃÀåÀ» ¾î¶»°Ô È®´ëÇϰí Àִ°¡?
À¯ÀüÇÐÀû °Ë»ç ½ÃÀåÀº Â÷¼¼´ë ½ÃÄö½Ì(NGS)°ú ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ(PCR)°ú °°Àº À¯ÀüÀÚ ½ÃÄö½Ì ±â¼úÀÇ ¹ßÀü¿¡ µû¶ó Å©°Ô º¯ÈÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº º¸´Ù ºü¸£°í Á¤È®ÇÏ¸ç ºñ¿ë È¿À²ÀûÀÎ À¯ÀüÀÚ ºÐ¼®À» °¡´ÉÇÏ°Ô ÇÏ¿© ±¤¹üÀ§ÇÑ À¯ÀüÀÚ º¯ÀÌÀÇ È®ÀÎÀ» ¿ëÀÌÇÏ°Ô ÇÏ¿´½À´Ï´Ù. DTC(Á÷Á¢ ¼ÒºñÀÚ¿ë) À¯ÀüÀÚ °Ë»ç ŰƮÀÇ ½ÅÈï±¹ ½ÃÀå °³Ã´Àº ½ÃÀåÀ» ´õ¿í È®´ëÇÏ¿© °³ÀÎÀÌ ÀÇ·á Á¦°ø¾÷ü¸¦ ÅëÇÏÁö ¾Ê°í À¯ÀüÇÐÀû °Ë»ç¿¡ Á¢±ÙÇÒ ¼ö ÀÖµµ·Ï Çß½À´Ï´Ù. °Ô´Ù°¡ ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º Åø°ú AIÀÇ ÅëÇÕÀº º¹ÀâÇÑ À¯ÀüÀÚ µ¥ÀÌÅ͸¦ ÇØ¼®ÇÏ´Â ´É·ÂÀ» °ÈÇÏ¿© À¯ÀüÀÚ¿Í È¯°æÀÇ »óÈ£ÀÛ¿ë°ú À¯Àü À§Çè¿¡ ´ëÇÑ º¸´Ù ±íÀº ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ ±â¼ú Çõ½ÅÀº ¶ÇÇÑ Ãâ»ý Àü°ú Âø»ó Àü À¯Àü ÇÐÀû °Ë»çÀÇ Á¤È®¼º°ú ½Å·Ú¼ºÀ» Çâ»ó½ÃŰ°íº¸´Ù ¾ÈÀüÇÑ »ý½Ä ÀÇ·á °áÁ¤À» º¸ÀåÇÕ´Ï´Ù.
½ÃÀå ¼¼ºÐÈ´Â ¾î¶»°Ô »ê¾÷À» Çü¼ºÇϴ°¡?
°Ë»çÀÇ À¯Çü¿¡´Â ¿¹Ãø °Ë»ç, ij¸®¾î °Ë»ç, Ãâ»ý Àü °Ë»ç, ½Å»ý¾Æ ½ºÅ©¸®´×ÀÌ ÀÖÀ¸¸ç, ¿¹Ãø °Ë»ç´Â ¾Ï µîÀÇ À¯Àü¼º ÁúȯÀÇ ¹ßº´ À§ÇèÀ» Æò°¡Çϴµ¥ ³Î¸® »ç¿ëµÇ°í Àֱ⠶§¹®¿¡ ÃÖ´ëÀÇ ºÎ¹®ÀÌ µË´Ï´Ù. À¯ÀüÇÐÀû °Ë»çÀÇ ¿ëµµ´Â Á¾¾çÇÐ, ½ÉÀ庴ÇÐ, »ý½ÄÀÇ·á, Èñ¼Ò À¯ÀüÀÚ Áúȯ µî ´Ù¾çÇÕ´Ï´Ù. Á¾¾çÇÐÀº ƯÈ÷ À¯¹æ¾Ï°ú ³¼Ò¾Ï°ú °ü·ÃµÈ BRCA1/BRCA2 º¯ÀÌÀÇ °ËÃâ¿¡ ÀÖ¾î¼ °¡Àå Áß¿äÇÑ ¿ëµµ¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÃÖÁ¾ ¿ëµµ ºÎ¹®Àº º´¿ø, Áø´Ü °Ë»ç ±â°ü, ¼ÒºñÀÚ¸¦ À§ÇÑ Á÷Á¢ °Ë»ç ¼ºñ½º¸¦ Æ÷ÇÔÇϸç, Áø´Ü °Ë»ç ±â°üÀº ÷´Ü À¯ÀüÀÚ °Ë»ç ´É·Â°ú ÀÎÇÁ¶ó¿¡ ÀÇÇØ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
À¯ÀüÇÐÀû °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?
À¯ÀüÇÐÀû °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀº À¯ÀüÀÚ Áúȯ¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡, À¯ÀüÀÚ ½ÃÄö½ÌÀÇ ±â¼úÀû Áøº¸, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. Áúº´ÀÇ Á¶±â ¹ß°ß°ú ¿¹¹æÀ» À§ÇÑ À¯ÀüÀÚ °Ë»çÀÇ Á߿伺¿¡ ´ëÇÑ ¼ÒºñÀÚ ÀÇ½Ä Áõ°¡´Â À¯ÀüÇÐÀû °Ë»ç ¼ºñ½º ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±â¼ú Çõ½Å, ƯÈ÷ Â÷¼¼´ë ½ÃÄö½Ì(NGS)Àº À¯ÀüÇÐÀû °Ë»ç¸¦ º¸´Ù ºü¸£°í, Á¤È®Çϰí, Àú°¡·Î ¸¸µé°í, ´õ ¸¹Àº »ç¶÷µé¿¡°Ô Á¢±ÙÀ» È®´ëÇß½À´Ï´Ù. °³ÀÎÀÇ À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏÀ» ±â¹ÝÀ¸·Î Ä¡·á °èȹÀ» Á¶Á¤ÇÏ´Â °³ÀÎÈµÈ ÇコÄÉ¾î ¼Ö·ç¼Ç¿¡ ´ëÇÑ °ü½É Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í °ÈÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ Á÷Á¢ ¼ÒºñÀڵ鿡°Ô Á¦°øµÇ´Â À¯ÀüÀÚ °Ë»ç ¼ºñ½ºÀÇ È®´ë·Î À¯ÀüÇÐÀû °Ë»ç¿¡ ´ëÇÑ Á¢±ÙÀÌ ¹ÎÁÖÈµÇ¾î °³ÀÎÀÌ À¯ÀüÀû ÅëÂû¿¡ ±Ù°ÅÇÏ¿© ÀÚ½ÅÀÇ °Ç°À» Àû±ØÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.
Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÁÖ¸ñÀÇ 39»ç)
- Agilent Technologies, Inc.
- CENTOGENE NV
- CooperSurgical, Inc.
- F. Hoffmann-La Roche Ltd
- Fulgent Genetic, Inc.
- Illumina, Inc.
- Invitae Corporation
- Laboratory Corporation of America Holdings
- Medgenome
- Myriad Genetics, Inc.
- Natera, Inc.
- Quest Diagnostics Incorporated
- Sophia Genetics
- Thermo Fisher Scientific, Inc.
- Twist Bioscience
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý
Á¦2Àå ÁÖ¿ä ¿ä¾à
- ½ÃÀå °³¿ä
- ÁÖ¿ä ±â¾÷
- ½ÃÀå µ¿Çâ°ú ÃËÁø¿äÀÎ
- ½ÃÀå Àü¸Á
Á¦3Àå ½ÃÀå ºÐ¼®
- ¹Ì±¹
- ij³ª´Ù
- ÀϺ»
- Áß±¹
- À¯·´
- ÇÁ¶û½º
- µ¶ÀÏ
- ÀÌÅ»¸®¾Æ
- ¿µ±¹
- ½ºÆäÀÎ
- ·¯½Ã¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- È£ÁÖ
- Àεµ
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- ¾Æ¸£ÇîÆ¼³ª
- ºê¶óÁú
- ¸ß½ÃÄÚ
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- 秵- À̶õ
- À̽º¶ó¿¤
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- ±âŸ Áßµ¿
- ¾ÆÇÁ¸®Ä«
Á¦4Àå °æÀï
BJH
Global Hereditary Testing Market to Reach US$11.8 Billion by 2030
The global market for Hereditary Testing estimated at US$7.8 Billion in the year 2023, is expected to reach US$11.8 Billion by 2030, growing at a CAGR of 6.1% over the analysis period 2023-2030. Preimplantation Genetic Diagnosis & Screening Test, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$4.6 Billion by the end of the analysis period. Growth in the Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests segment is estimated at 6.1% CAGR over the analysis period.
The U.S. Market is Estimated at US$2.1 Billion While China is Forecast to Grow at 9.1% CAGR
The Hereditary Testing market in the U.S. is estimated at US$2.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2030 trailing a CAGR of 9.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.
Global Hereditary Testing Market - Key Trends and Drivers Summarized
Why Is Hereditary Testing Revolutionizing Personalized Medicine?
Hereditary testing has become a transformative tool in modern medicine, enabling the detection of genetic mutations associated with inherited diseases and conditions. It plays a critical role in diagnosing genetic disorders, guiding personalized treatment plans, and informing patients of their potential risk of passing on genetic traits to their offspring. Hereditary testing encompasses a wide range of applications, including cancer risk assessment, reproductive health, and cardiovascular diseases. As the cost of genetic sequencing continues to decrease, hereditary testing has become more accessible, empowering individuals with valuable insights into their health and enabling early intervention or preventive care measures. With advancements in genomic science, hereditary testing is now a cornerstone of personalized medicine, providing tailored healthcare solutions based on individual genetic profiles.
How Are Technological Advancements Expanding the Hereditary Testing Market?
The hereditary testing market has been revolutionized by advancements in genetic sequencing technologies, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR). These technologies allow for faster, more accurate, and cost-effective genetic analysis, making it easier to identify mutations across a broad range of genes. The development of direct-to-consumer (DTC) genetic testing kits has further expanded the market, enabling individuals to access hereditary testing without the need for a healthcare provider. Moreover, the integration of bioinformatics tools and AI has enhanced the ability to interpret complex genetic data, providing deeper insights into gene-environment interactions and hereditary risks. These innovations are also improving the accuracy and reliability of prenatal and preimplantation genetic testing, ensuring safer reproductive health decisions.
How Are Market Segments Shaping the Hereditary Testing Industry?
Test types include predictive testing, carrier testing, prenatal testing, and newborn screening, with predictive testing being the largest segment due to its widespread use in assessing the risk of developing inherited conditions such as cancer. Applications of hereditary testing range from oncology and cardiology to reproductive health and rare genetic disorders. Oncology represents the most significant application, particularly in detecting BRCA1/BRCA2 mutations linked to breast and ovarian cancers. The end-use segment includes hospitals, diagnostic laboratories, and direct-to-consumer testing services, with diagnostic laboratories holding the largest share due to their advanced genetic testing capabilities and infrastructure.
What Factors Are Driving the Growth in the Hereditary Testing Market?
The growth in the hereditary testing market is driven by several factors, including increasing awareness of genetic disorders, technological advancements in genetic sequencing, and the growing demand for personalized medicine. Rising awareness among consumers about the importance of genetic testing for early disease detection and prevention is fueling demand for hereditary testing services. Technological innovations, particularly in next-generation sequencing (NGS), have made hereditary testing faster, more accurate, and affordable, expanding its accessibility to a broader population. The growing focus on personalized healthcare solutions, where treatment plans are tailored based on individual genetic profiles, is further boosting market growth. Additionally, the expansion of direct-to-consumer genetic testing services has democratized access to hereditary testing, allowing individuals to proactively manage their health based on genetic insights.
Select Competitors (Total 39 Featured) -
- Agilent Technologies, Inc.
- CENTOGENE N.V.
- CooperSurgical, Inc.
- F. Hoffmann-La Roche Ltd
- Fulgent Genetic, Inc.
- Illumina, Inc.
- Invitae Corporation
- Laboratory Corporation of America Holdings
- Medgenome
- Myriad Genetics, Inc.
- Natera, Inc.
- Quest Diagnostics Incorporated
- Sophia Genetics
- Thermo Fisher Scientific, Inc.
- Twist Bioscience
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Global Economic Update
- Hereditary Testing - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Prevalence of Genetic Disorders Drives Demand for Hereditary Testing
- Technological Advancements in Genomic Sequencing Propel Growth in Hereditary Testing
- Growing Focus on Personalized Medicine Expands Addressable Market for Genetic Testing
- Increasing Awareness About Genetic Predisposition to Diseases Spurs Demand for Hereditary Testing
- Expansion of Direct-to-Consumer (DTC) Genetic Testing Strengthens Business Case for Hereditary Testing Solutions
- Rising Demand for Non-Invasive Prenatal Testing (NIPT) Drives Market Growth
- Surge in Genetic Counseling Services Expands Opportunities for Hereditary Testing
- Growing Use of Hereditary Testing in Oncology Drives Market Innovation
- Increasing Focus on Early Disease Detection and Prevention Spurs Growth in Genetic Testing
- Expansion of Telehealth Platforms Strengthens Access to Hereditary Testing Services
- Technological Integration of AI and Big Data in Genomic Testing Expands Market Potential
- Increasing Demand for Carrier Screening in Family Planning Drives Adoption of Hereditary Testing
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Hereditary Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 2: World Historic Review for Hereditary Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 3: World 16-Year Perspective for Hereditary Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis & Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 5: World Historic Review for Preimplantation Genetic Diagnosis & Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 6: World 16-Year Perspective for Preimplantation Genetic Diagnosis & Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 8: World Historic Review for Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 9: World 16-Year Perspective for Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 10: World Recent Past, Current & Future Analysis for Genetic Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 11: World Historic Review for Genetic Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 12: World 16-Year Perspective for Genetic Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 13: World Recent Past, Current & Future Analysis for Newborn Genetic Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 14: World Historic Review for Newborn Genetic Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 15: World 16-Year Perspective for Newborn Genetic Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 16: World Recent Past, Current & Future Analysis for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 17: World Historic Review for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 18: World 16-Year Perspective for Other Test Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 19: World Recent Past, Current & Future Analysis for Molecular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 20: World Historic Review for Molecular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 21: World 16-Year Perspective for Molecular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 22: World Recent Past, Current & Future Analysis for Cytogenetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 23: World Historic Review for Cytogenetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 24: World 16-Year Perspective for Cytogenetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 25: World Recent Past, Current & Future Analysis for Biochemical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 26: World Historic Review for Biochemical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 27: World 16-Year Perspective for Biochemical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 28: World Hereditary Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
- UNITED STATES
- Hereditary Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 29: USA Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 30: USA Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 31: USA 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 32: USA Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 33: USA Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 34: USA 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- CANADA
- TABLE 35: Canada Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 36: Canada Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 37: Canada 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 38: Canada Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 39: Canada Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 40: Canada 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- JAPAN
- Hereditary Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 41: Japan Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 42: Japan Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 43: Japan 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 44: Japan Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 45: Japan Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 46: Japan 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- CHINA
- Hereditary Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 47: China Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 48: China Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 49: China 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 50: China Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 51: China Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 52: China 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- EUROPE
- Hereditary Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 53: Europe Recent Past, Current & Future Analysis for Hereditary Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 54: Europe Historic Review for Hereditary Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 55: Europe 16-Year Perspective for Hereditary Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
- TABLE 56: Europe Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 57: Europe Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 58: Europe 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 59: Europe Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 60: Europe Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 61: Europe 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- FRANCE
- Hereditary Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 62: France Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 63: France Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 64: France 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 65: France Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 66: France Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 67: France 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- GERMANY
- Hereditary Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 68: Germany Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 69: Germany Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 70: Germany 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 71: Germany Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 72: Germany Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 73: Germany 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- ITALY
- TABLE 74: Italy Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 75: Italy Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 76: Italy 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 77: Italy Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 78: Italy Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 79: Italy 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- UNITED KINGDOM
- Hereditary Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 80: UK Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 81: UK Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 82: UK 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 83: UK Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 84: UK Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 85: UK 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- SPAIN
- TABLE 86: Spain Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 87: Spain Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 88: Spain 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 89: Spain Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 90: Spain Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 91: Spain 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- RUSSIA
- TABLE 92: Russia Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 93: Russia Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 94: Russia 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 95: Russia Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 96: Russia Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 97: Russia 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- REST OF EUROPE
- TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 99: Rest of Europe Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 100: Rest of Europe 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 102: Rest of Europe Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 103: Rest of Europe 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- ASIA-PACIFIC
- Hereditary Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Hereditary Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 105: Asia-Pacific Historic Review for Hereditary Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 106: Asia-Pacific 16-Year Perspective for Hereditary Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
- TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 108: Asia-Pacific Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 109: Asia-Pacific 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 111: Asia-Pacific Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 112: Asia-Pacific 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- AUSTRALIA
- Hereditary Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
- TABLE 113: Australia Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 114: Australia Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 115: Australia 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 116: Australia Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 117: Australia Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 118: Australia 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- INDIA
- Hereditary Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
- TABLE 119: India Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 120: India Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 121: India 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 122: India Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 123: India Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 124: India 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- SOUTH KOREA
- TABLE 125: South Korea Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 126: South Korea Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 127: South Korea 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 128: South Korea Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 129: South Korea Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 130: South Korea 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- REST OF ASIA-PACIFIC
- TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 132: Rest of Asia-Pacific Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 135: Rest of Asia-Pacific Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- LATIN AMERICA
- Hereditary Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
- TABLE 137: Latin America Recent Past, Current & Future Analysis for Hereditary Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 138: Latin America Historic Review for Hereditary Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 139: Latin America 16-Year Perspective for Hereditary Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
- TABLE 140: Latin America Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 141: Latin America Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 142: Latin America 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 143: Latin America Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 144: Latin America Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 145: Latin America 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- ARGENTINA
- TABLE 146: Argentina Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 147: Argentina Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 148: Argentina 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 149: Argentina Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 150: Argentina Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 151: Argentina 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- BRAZIL
- TABLE 152: Brazil Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 153: Brazil Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 154: Brazil 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 155: Brazil Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 156: Brazil Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 157: Brazil 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- MEXICO
- TABLE 158: Mexico Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 159: Mexico Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 160: Mexico 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 161: Mexico Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 162: Mexico Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 163: Mexico 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- REST OF LATIN AMERICA
- TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 165: Rest of Latin America Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 166: Rest of Latin America 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 168: Rest of Latin America Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 169: Rest of Latin America 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- MIDDLE EAST
- Hereditary Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
- TABLE 170: Middle East Recent Past, Current & Future Analysis for Hereditary Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 171: Middle East Historic Review for Hereditary Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 172: Middle East 16-Year Perspective for Hereditary Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
- TABLE 173: Middle East Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 174: Middle East Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 175: Middle East 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 176: Middle East Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 177: Middle East Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 178: Middle East 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- IRAN
- TABLE 179: Iran Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 180: Iran Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 181: Iran 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 182: Iran Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 183: Iran Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 184: Iran 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- ISRAEL
- TABLE 185: Israel Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 186: Israel Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 187: Israel 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 188: Israel Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 189: Israel Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 190: Israel 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- SAUDI ARABIA
- TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 192: Saudi Arabia Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 193: Saudi Arabia 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 195: Saudi Arabia Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 196: Saudi Arabia 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- UNITED ARAB EMIRATES
- TABLE 197: UAE Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 198: UAE Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 199: UAE 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 200: UAE Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 201: UAE Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 202: UAE 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- REST OF MIDDLE EAST
- TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 204: Rest of Middle East Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 205: Rest of Middle East 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 207: Rest of Middle East Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 208: Rest of Middle East 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
- AFRICA
- Hereditary Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
- TABLE 209: Africa Recent Past, Current & Future Analysis for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 210: Africa Historic Review for Hereditary Testing by Test Type - Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 211: Africa 16-Year Perspective for Hereditary Testing by Test Type - Percentage Breakdown of Value Sales for Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening and Other Test Types for the Years 2014, 2024 & 2030
- TABLE 212: Africa Recent Past, Current & Future Analysis for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 213: Africa Historic Review for Hereditary Testing by Technology - Molecular, Cytogenetic and Biochemical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 214: Africa 16-Year Perspective for Hereditary Testing by Technology - Percentage Breakdown of Value Sales for Molecular, Cytogenetic and Biochemical for the Years 2014, 2024 & 2030
IV. COMPETITION